Alnylam Pharmaceuticals Projects Powerful Growth After Breakout Year
Alnylam Pharmaceuticals ((ALNY)) has held its Q4 earnings call. Read on for the main highlights of the call.
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Alnylam Pharmaceuticals’ latest earnings call radiated strong optimism, as management leaned on transformational 2025 results to argue the story is still in the early innings of a growth cycle. Rapid product sales expansion, newfound profitability and a deepening pipeline set a bullish tone, even as executives flagged nearer-term pressures on margins, pricing and quarterly revenue phasing.
Record Revenue Surge Driven by Amvuttra Launch
Alnylam reported nearly $3.0 billion in global net product revenue for 2025, an 81% jump versus 2024 that firmly reset the company’s scale. The surge was powered mainly by the U.S. launch of Amvuttra for ATTR cardiomyopathy, which has rapidly emerged as the centerpiece of the firm’s commercial engine.
Q4 Delivers Breakout Quarter for TTR Franchise
Fourth-quarter 2025 combined net product revenue reached $995 million, up 121% year over year and 17% sequentially, underscoring accelerating momentum into year‑end. The TTR franchise alone generated $858 million in Q4, rising 151% from a year earlier and 18% quarter on quarter as uptake broadened.
Profitability Milestone Marks Strategic Inflection Point
Alnylam crossed a critical threshold by achieving both GAAP and non‑GAAP net income profitability in Q4 and for the full year 2025, validating the scalability of its RNAi model. Non‑GAAP operating income for 2025 reached $850 million, a $755 million improvement versus the prior year that gives the company more strategic flexibility.
Commercial Momentum in TTR and Rare Diseases Builds Scale
Management highlighted the TTR franchise as the primary growth engine, with Amvuttra adoption in the U.S. approaching parity with tafamidis in new patient starts soon after launch. In parallel, the rare disease portfolio stayed resilient, generating $136 million in Q4 revenue, up 26% year over year, and turning GIVLAARI plus OXLUMO into a $500 million franchise in 2025.
Alnylam 2030: Ambitious Long-Term Growth Blueprint
Under its Alnylam 2030 strategy, the company is targeting revenue compound annual growth above 25% through 2030 and a 30% non‑GAAP operating margin across the period. Management plans to invest about 30% of revenues into non‑GAAP R&D while expanding to over 40 clinical programs and reaching 10 tissue types, signaling a long runway for platform expansion.
Pipeline Advances with Multiple Phase 3 Starts
R&D momentum continued as Alnylam initiated three Phase 3 trials in 2025, including ZENITH for zalesiran with roughly 11,000 patients and the TRITON‑CM and TRITON‑PN studies for nuceresiran. The overall clinical pipeline now spans more than 25 active programs, supported by four new Alnylam‑led clinical trial applications filed during the year.
Manufacturing Platform Cyrillis Targets Scale and Efficiency
The company unveiled Cyrillis, an enzymatic ligation‑based RNAi manufacturing platform designed to boost capacity and lower cost of goods as volumes scale. Management framed this innovation as a strategic lever, enabling broader patient reach and potentially supporting better long‑term margins as the product portfolio expands.
Balance Sheet Strength and Partnership Upside
Alnylam ended 2025 with $2.9 billion in cash, cash equivalents and marketable securities, up $200 million from the prior year, giving it firepower to fund its pipeline and launches. Collaboration revenue climbed to $553 million, up 8% year over year, while royalty revenue nearly doubled to $104 million, adding diversified and growing income streams.
Gross Margin Pressure from Rising Royalties
Despite the revenue surge, full‑year gross margin on product sales slipped to 77%, down four percentage points versus 2024. Management tied the compression largely to higher royalties owed to Sanofi on Amvuttra as that product’s revenue base expands, a trade‑off between top‑line acceleration and near‑term profitability.
Pricing Headwinds Temper U.S. Amvuttra Outlook
Looking ahead, the company expects a mid‑single‑digit net price decline for Amvuttra in the U.S. in 2026, mirroring the pattern seen in 2025. Executives stressed that these reductions should be gradual over the year, implying volume growth and category expansion will need to offset the pricing drag.
Q1 2026 Revenue Phasing to Mask Underlying Growth
Management cautioned that TTR revenue growth in Q1 2026 will appear considerably softer on a sequential basis due to several timing factors rather than demand weakness. These include an approximate $25 million reduction in international revenue tied to pricing alignment, fewer shipping weeks and routine annual insurance reauthorizations.
One-Time Milestones Create Tough Collaboration Revenue Compare
Collaboration and royalty revenue guidance of $400 million to $500 million for 2026 implies about a 38% decline at the midpoint versus 2025. The drop is mainly mechanical, reflecting the non‑recurrence of a one‑off $300 million milestone from zalesiran booked in 2025, which sets up a difficult year‑over‑year comparison.
Rising Operating Spend Fuels Pipeline and Launches
Non‑GAAP R&D spending rose 17% in 2025 to about $1.2 billion, while non‑GAAP SG&A grew 22% to roughly $1.0 billion as Alnylam scaled its commercial footprint. For 2026, combined non‑GAAP R&D and SG&A is guided between $2.7 billion and $2.8 billion, about 26% growth at the midpoint, reflecting heavy investment behind late‑stage programs and new indications.
Competitive and Label Risks Cloud Longer-Term TTR Picture
Management acknowledged elevated uncertainty from potential new entrants and upcoming competitive silencer data expected in 2026, which could influence future labeling and commercial dynamics. Executives said it is too early to quantify any 2027 impact, emphasizing they will track safety, efficacy and key readouts closely before resetting expectations.
Clinical Execution Remains Critical to Margin Upside
The company’s longer‑term margin and growth aspirations hinge on successful late‑stage execution, particularly for nuceresiran and other 2028–2030 assets. Alnylam has pointed to the possibility of mid‑40s operating margins after 2030 if nuceresiran proves best in class, but those benefits remain contingent on favorable Phase 3 outcomes and regulatory approvals.
Germany Pricing Alignment Creates Near-Term Drag, Long-Term Opportunity
Recent pricing alignment for Amvuttra cardiomyopathy in Germany is expected to trim TTR revenue modestly in the near term, with Q1 2026 facing about a $25 million international impact. Management argued that the new pricing structure should ultimately enable broader participation in the larger cardiomyopathy market, supporting longer‑term international growth.
Guidance Signals Aggressive 2026 Growth Despite Headwinds
Alnylam reiterated 2026 combined net product revenue guidance of $4.9 billion to $5.3 billion, implying roughly 71% growth at the midpoint over 2025, with rare disease revenue set for mid‑single‑digit growth and TTR expected to surge about 83%. Collaboration and royalty revenue is guided to $400 million to $500 million, while non‑GAAP R&D plus SG&A is projected at $2.7 billion to $2.8 billion, and management reiterated long‑term goals of more than 25% revenue CAGR and 30% non‑GAAP operating margins through 2030.
Alnylam’s earnings call painted a picture of a company transitioning from a promising biotech to a scaled, profitable RNAi leader, with the TTR franchise and Amvuttra at the core of its growth story. While investors must weigh pricing, competition and execution risks, management’s detailed strategy, strong balance sheet and robust guidance suggest the growth trajectory remains firmly intact.
